Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
DJ Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
By Matt Grossman
Merck & Co. Inc.'s Keytruda drug met the primary endpoint of a Phase 3 trial to evaluate its use in treating an additional form of cancer, the Kenilworth, N.J.-based pharmaceutical company said Thursday.
The trial evaluated Keytruda's use as an adjuvant treatment for people with renal cell carcinoma following a nephrectomy, or a nephrectomy and the resection of metastatic lesions. Nephrectomy is the removal of a kidney. In the trial, which included 950 patients, subjects received either Keytruda or a placebo.
Keytruda led to a meaningful improvement in disease-free survival compared with the placebo in the trial, Merck said. Researchers will continue to evaluate overall survival among the patients in the trial.
Dr. Roy Baynes, Merck Research Laboratories' chief medical officer, said the company would share detailed results from the trial with regulators as soon as possible.
Keytruda, or pembrolizumab, has already been approved in the U.S. for roles in treating other forms of cancer.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 08, 2021 07:01 ET (11:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
DJ默克公司的抗癌药物Keytruda在3期试验中遇到主要终点
By Matt Grossman
马特·格罗斯曼(Matt Grossman)著
Merck & Co. Inc.'s Keytruda drug met the primary endpoint of a Phase 3 trial to evaluate its use in treating an additional form of cancer, the Kenilworth, N.J.-based pharmaceutical company said Thursday.
总部位于新泽西州凯尼尔沃斯的默克公司(Merck&Co.Inc.)周四表示，该公司的Keytruda药物达到了3期试验的主要终点，该试验旨在评估其在治疗另一种癌症方面的使用情况。
The trial evaluated Keytruda's use as an adjuvant treatment for people with renal cell carcinoma following a nephrectomy, or a nephrectomy and the resection of metastatic lesions. Nephrectomy is the removal of a kidney. In the trial, which included 950 patients, subjects received either Keytruda or a placebo.
这项试验评估了Keytruda作为肾癌患者在肾切除、肾切除和转移病灶切除后的辅助治疗。肾切除术就是切除肾脏。在这项包括950名患者的试验中，受试者接受了Keytruda或安慰剂。
Keytruda led to a meaningful improvement in disease-free survival compared with the placebo in the trial, Merck said. Researchers will continue to evaluate overall survival among the patients in the trial.
默克说，与试验中的安慰剂相比，Keytruda导致了无病生存率的显著改善。研究人员将继续评估试验中患者的总体存活率。
Dr. Roy Baynes, Merck Research Laboratories' chief medical officer, said the company would share detailed results from the trial with regulators as soon as possible.
默克研究实验室首席医疗官Roy Baynes博士表示，该公司将尽快与监管机构分享试验的详细结果。
Keytruda, or pembrolizumab, has already been approved in the U.S. for roles in treating other forms of cancer.
Keytruda，或pembrolizumab，已经在美国被批准用于治疗其他形式的癌症。
Write to Matt Grossman at matt.grossman@wsj.com
写信给马特·格罗斯曼(Matt Grossman)，电子邮件：matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
April 08, 2021 07:01 ET (11:01 GMT)
2021年4月8日07：01美国东部时间(格林尼治标准时间11：01)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧